Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.58 EUR+1.02 %17/9 13:34
5,670 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
+1.02 %
-3.89 %
+11.11 %
-35.77 %
-58.09 %
-57.81 %
-46.89 %
-86.50 %
-65.50 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
33.96M EUR
Turnover
37.15K EUR
P/E (adj.) (26e)
-12.48
EV/EBIT (adj.) (26e)
-8.91
P/B (26e)
1.59
EV/S (26e)
1.65
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
2026-08-17
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-08-17

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
[quote="Dr.Feelgood, post:6820, topic:2389"]\nPöhinä is a relative concept. Is yellow a single LinkedIn post, orange participation in a trade fair, and red spotted on the community’s own pages?\n[/quote]\n\nNot that simple. \nWe are monitoring signs of Optomed/Aurora AEYE’s commercial...
5 hours ago
by Puutaheinää
28
Here’s this picture, AI makes it, or an agent setup (agenttiviritys) always on Wednesdays spits one out for me, ever since around Midsummer. Little by little more colors are showing up, and it’s getting darker too. Nothing special, since people don’t really want AI stuff here so ...
21 hours ago
by Puutaheinää
24
I’m tweaking it a bit while I have the time. Now it apparently scanned 120 data sources; in some states the coverage is clearly too thin, while in others it’s close to ten sites. I’ll have it peer-learn how to scout out states. By the way, this kind of work would also be helpful ...
4 hours ago
by Puutaheinää
16
[quote="Kulukurssi, post:6816, topic:2389"]\n@Juha_Kinnunen Whereabouts have you planned the next comprehensive report? Has there really happened so much globally/at Optomed that it would already justify a broader update?\n\n[/quote]\n\nIt is definitely on the update list. However...
yesterday
by Juha Kinnunen
16
I used AI myself and took the analysis of this LinkedIn post further. The original source is always the most important. The AI actually found the statement from September 7, 2026, by China’s National Health Commission and Center for Disease Control and Prevention (i.e., the NHC, ...
yesterday
by Dr.Feelgood
16
Good day! I also discussed this with the AI. Yes, the official guidelines do include that coverage indicator. And reimbursement is also real. Grok wrote that the customer pays 15-30% per imaging session and insurance covers the rest. Several media outlets have also written about ...
yesterday
by j.sälli
9
This is simple; US states in roughly geographical order, and the redder the color, the more Optomed buzz based on public sources. Buzz is a relative concept. Is yellow one LinkedIn post, orange participation in a trade show, and red something spotted on the community’s own pages?
19 hours ago
by Dr.Feelgood
8
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

4/5
2027

Interim report Q1'27

Optomeds dotterbolag Ubetec vann Veikkauchs anbudsförfarande
Analyst Comment2026-09-07 06:55 by
Juha Kinnunen

Optomeds dotterbolag Ubetec vann Veikkauchs anbudsförfarande

Veikkaus avtalstilldelning på 0,9 MEUR stärker dotterbolaget Ubetecs position på den finländska spelmarknaden som håller på att öppnas upp.

Optomed
Regulatory press release2026-09-04 14:00

Optomed Oyj: Composition of Optomed's Shareholders' Nomination Board

Optomed
Press release2026-08-18 13:10

Redeye: Optomed (Q2 Review): Sales miss offset by strong gross margin and cost control

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Optomed Q2'26: Apparatförsäljningen drar inte, men de återkommande intäkterna växer
Research2026-08-17 07:00 by
Juha Kinnunen

Optomed Q2'26: Apparatförsäljningen drar inte, men de återkommande intäkterna växer

Optomeds omsättning och vinst i Q2 var betydligt lägre än våra förväntningar, då försäljningen av utrustning fortsatte att vara svag. Positivt i rapporten var den fortsatta tillväxten i försäljningen av Aurora AEYE, minskade kostnader, ett tydligt återhämtat kassaflöde och en rekordhög bruttomarginal.

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Tauriainen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Leppänen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Wen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Salonen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Lee

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Badlani

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release2026-08-14 08:30

Optomed Oyj: Directed share issue without payment to implement Board remuneration

Optomed
Regulatory press release2026-08-14 08:30

Optomed Oyj: Optomed's financial reporting in 2027

Optomed
Regulatory press release2026-08-14 08:00

Optomed Plc: Half-year report January - June 2026

Optomed
Optomed Q2'26 förhandskommentar: Vi förväntar oss en återgång till tillväxt och övervakar kassaflödet
Analyst Comment2026-08-11 07:02 by
Juha Kinnunen

Optomed Q2'26 förhandskommentar: Vi förväntar oss en återgång till tillväxt och övervakar kassaflödet

Vi estimerar att omsättningen har ökat i takt med att försäljningen av utrustning återhämtat sig från en svag inledning på året.

Optomed
Press release2026-06-23 09:43

Redeye: Optomed: Solid device order

Optomed
Optomed fick en order på 1,8 MEUR för utrustning från USA
Analyst Comment2026-06-22 06:58 by
Atte Riikola

Optomed fick en order på 1,8 MEUR för utrustning från USA

Ordern överstiger hela årets intäkter från utrustning och stärker kassan.

Optomed
Regulatory press release2026-06-18 16:30

Inside Information: Optomed receives a large order in the US

Optomed
Press release2026-05-11 15:16

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed